Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1153

1.
2.

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.

Ann Intern Med. 2003 Apr 1;138(7):542-9.

PMID:
12667024
3.

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.

PMID:
14586737
4.

The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.

Nephrol Dial Transplant. 2000 Apr;15(4):487-97.

5.

The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.

Busch M, Franke S, Wolf G, Brandstädt A, Ott U, Gerth J, Hunsicker LG, Stein G; Collaborative Study Group.

Am J Kidney Dis. 2006 Oct;48(4):571-9.

PMID:
16997053
6.

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.

Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ.

J Am Soc Nephrol. 2005 Oct;16(10):3027-37. Epub 2005 Aug 24.

7.

Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.

Engelen L, Persson F, Ferreira I, Rossing P, Hovind P, Teerlink T, Stehouwer CD, Parving HH, Schalkwijk CG.

Nephrol Dial Transplant. 2011 Nov;26(11):3573-7. doi: 10.1093/ndt/gfr102. Epub 2011 Mar 8.

8.

A clinical trial in type 2 diabetic nephropathy.

Lewis EJ, Hunsicker LG, Rodby RA; Collaborative Study Group.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S191-4.

PMID:
11576953
9.

[Is the serum concentration of pentosidine a predictor of cardiovascular events in patients with type 2 diabetes and kidney disease?].

Busch M, Franke S, Stein G, Wolf G; Collaborative Study Group.

Dtsch Med Wochenschr. 2007 Sep;132(36):1810-4. German.

PMID:
17726651
10.

Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.

Miura J, Yamagishi Si, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y.

J Diabetes Complications. 2003 Jan-Feb;17(1):16-21.

PMID:
12505751
11.

Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

Croom KF, Curran MP, Goa KL, Perry CM.

Drugs. 2004;64(9):999-1028. Review.

PMID:
15101793
12.

[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Ritz E.

Dtsch Med Wochenschr. 2004 Jan 2;129(1-2):13-8. German.

PMID:
14703575
13.

Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.

Rabbani N, Adaikalakoteswari A, Rossing K, Rossing P, Tarnow L, Parving HH, Thornalley PJ.

Amino Acids. 2012 May;42(5):1627-39. doi: 10.1007/s00726-011-0857-7. Epub 2011 Mar 8.

PMID:
21384133
14.

Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.

Gohda T, Tanimoto M, Moon JY, Gotoh H, Aoki T, Matsumoto M, Shibata T, Ohsawa I, Funabiki K, Tomino Y.

Diabetes Res Clin Pract. 2008 Aug;81(2):196-201. doi: 10.1016/j.diabres.2008.04.013. Epub 2008 Jun 11.

PMID:
18550199
16.

Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN).

Schiel R, Franke S, Appel T, Voigt U, Ross IS, Kientsch-Engel R, Stein G, Müller UA.

J Diabetes Complications. 2003 Mar-Apr;17(2):90-7.

PMID:
12614975
17.

Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.

Neutel JM, Germino FW, Smith D.

J Renin Angiotensin Aldosterone Syst. 2005 Sep;6(2):84-9.

PMID:
16470487
18.

Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.

Evans M, Bain SC, Hogan S, Bilous RW; Collaborative Study Group participants.

Nephrol Dial Transplant. 2012 Jun;27(6):2255-63. doi: 10.1093/ndt/gfr696. Epub 2011 Dec 15.

20.

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group.

N Engl J Med. 2001 Sep 20;345(12):851-60.

Items per page

Supplemental Content

Write to the Help Desk